Xi’an Salus Nutra Inc Established in 2015 and located in Hi-Tech industrial Zone in xi’an city, which is the most advanced area in northwest china . Salus Nutra is a professional company specialized in natural plant extracts, collagen and high technology chemical API field in scientific research, producing and marketing.

Our products are mainly used in healthcare supplement, chemicals ,pharmaceutical, cosmetics and food additives. We are also engaged in supplying customization OEM service to help customers choose their right ingredients and develop their broad markets .

Our factory is located in BaoJi ,shaanxi province, it coveries an area of XX acres and equips with 2 standard production workshops meet with State Health Standards ,meanwhile employs more than 500 people with well-educated, including undergraduate, Postgraduate and some technical persons with rich experience.

Salus is committed to supplying safe, pure and healthy products that meet the high expectations of our customers. Experienced and dedicated members of the Quality and food safety Department work to provide in-depth analyses, testing and monitoring of our products, during and after the manufacturing processes and ensure the quality and safety according to the highest standards.

We are based on the honest and mutual benefits, rely on the reliable quality and best after-sale service to make good reputations both online and offline. Now it shares a great popularities from the customers at overseas. Our primary goal aims to solve customer problems through research & development & technical service .

If you have any doubts or confusion, YES, Salus will present the exactly right answer.

Top Grade Liraglutide

1)Product Name:factory Supply High purity Liraglutide,Cas#204656-20-2, Treatment of diabetic

2)CAS:204656-20-2

3)Molecular Formula:C172H265N43O51

4)Molecular Weight:267.23

5)Assay:99%

6)Appearance:White or colourless crystalline powder with characteristic odor

Liraglutide improves control of blood glucose.It reduces meal-related hyperglycemia (for 24 hours after administration) by increasing insulin secretion (only) when required by increasing glucose levels, delaying gastric emptying, and suppressing prandial glucagon secretion.

In common to various degrees with other GLP-1 receptor agonists, liraglutide has advantages over more traditional therapies for type 2 diabetes:

1).It acts in a glucose-dependent manner, meaning it will stimulate insulin secretion only when blood glucose levels are higher than normal, preventing "overshoot". Consequently, it shows negligible risk of hypoglycemia.

2).It has the potential for inhibiting apoptosis and stimulating regeneration of beta cells (seen in animal studies).

3).It decreases appetite and inhibits body weight gain, as shown in a head-to-head study versus glimepiride.

4).It lowers blood triglyceride levels.

Liraglutide (NN2211) is a long-acting glucagon-like peptide-1 receptor agonist, binding to the same receptors as does the endogenous metabolic hormone GLP-1 that stimulates insulin secretion. Marketed under the brand name Victoza, it is an injectable drug developed by Novo Nordisk for the treatment oftype 2 diabetes. In 2015, Novo Nordisk began marketing it in the U.S. and E.U. under the brand name Saxenda as a treatment for adults, who are obese or overweight with at least one weight-relatedcomorbid condition.